Major players benefit from industry consolidation
This article was originally published in Clinica
Consolidation in the medical devices and diagnostics industry over the last 10 years has reinforced the position of the large players to the benefit of both US and EU companies. According to the LEK consultancy, the combined market share of the top 30 European and US companies increased from 49% in 1988 to 56% in 1992 (US companies 35%, EU 21%):
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.